Arvinas, Inc.
HealthcareNASDAQ:ARVN · NASDAQ Global Select
+$0.49 today
Vol 0.86M · Avg 0.89M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-18.6%
avg -1010.5%
ROIC
-19.9%
avg -29.9%
ROA
-11.3%
avg -22.7%
Analysis
ROA is currently the strongest return metric at -11.3% versus its period average of -22.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Noah Berkowitz | Chief Medical Officer | $834,887.00 | — | 62 | $191,395.00 | 0.30% |
Andrew Saik | Chief Financial Officer & Treasurer | $819,563.00 | — | 57 | $193,128.00 | 0.30% |
Angela Cacace | Chief Scientific Officer | $758,163.00 | — | 58 | $182,966.00 | 0.28% |
Randy Teel | CEO, President & Director | $711,098.00 | — | 46 | $285,009.00 | 0.44% |
Jared Freedberg | General Counsel & Corporate Secretary | — | — | 57 | — | — |
Alexander A. Santini | Chief Commercial Officer | — | — | 67 | — | — |
David Loomis | Vice President & Chief Accounting Officer | — | — | 52 | $40,193.00 | 0.06% |
Jeff Boyle | Vice President of Investor Relations | — | — | — | — | — |
Paul McInulty | Senior Vice President of Regulatory Affairs | — | — | — | — | — |
Steve Weiss | Senior Vice President & Chief Human Resources Officer | — | — | 56 | — | — |
Kelly Page | Senior Vice President & Global Head of Oncology Strategy and Program Leadership | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$495,080.00
Sells
23
$1.42M
Net Sentiment
$922,767.98
Net selling
Most Active
Teel Randy
5 transactions
1–10 of 25
Analysis
Insiders reported 2 buys worth $495,080.00 and 23 sells worth $1.42M over the last 12 months. That adds up to net selling of $922,767.98. Teel Randy was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +50.6% | +20.0% (10yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +50.6% over three years. Forward estimates point to Revenue at +20.0% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.37B
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.46B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.42B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Geron Corporation
NASDAQ:GERN
$737.75M
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Astria Therapeutics, Inc.
ATXS
$718.13M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
Valneva SE
NASDAQ:VALN
$507.78M
Who manages ARVN?
Arvinas, Inc. (ARVN) lists 11 active executives. The top listed executive is Andrew Saik, Chief Financial Officer & Treasurer.
Are ARVN insiders buying or selling?
Recent insider activity shows net buying of $31.05M.
Explore More
Continue the stock analysis
Jump to another research area for this company.